Brewin Dolphin Wealth Management’s Dianthus Therapeutics DNTH Stock Holding History

Brewin Dolphin Wealth Management’s Portfolio DNTH Stock Details DNTH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	$2K	Hold	81	–	–	﹤0.01%	327
2022 Q1	$4K	Hold	81	–	–	﹤0.01%	328
2021 Q4	$6K	Hold	81	–	–	﹤0.01%	292
2021 Q3	$9.46K	Hold	81	–	–	﹤0.01%	300
2021 Q2	$12.7K	Hold	81	–	–	﹤0.01%	289
2021 Q1	$15.4K	Buy	81 +47	+138%	+$7.91K	﹤0.01%	274
2020 Q4	$4.31K	Hold	34	–	–	﹤0.01%	266
2020 Q3	$3.74K	Hold	34	–	–	﹤0.01%	271
2020 Q2	$4.13K	Hold	34	–	–	﹤0.01%	272
2020 Q1	$3.45K	Hold	34	–	–	﹤0.01%	188
2019 Q4	$8.34K	Hold	34	–	–	﹤0.01%	180
2019 Q3	$5.64K	Buy	+34	New	+$6.46K	﹤0.01%	183

Other funds holding DNTH

TGI

TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

AVLSA

Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return

Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Brewin Dolphin Wealth Management's DNTH Position: Q2 2022 in Review

Brewin Dolphin Wealth Management held its Dianthus Therapeutics (DNTH) position steady in Q2 2022 at 81 shares worth $2K. The position accounts for ﹤0.01% of the portfolio, ranked #327.

Brewin Dolphin Wealth Management first reported a position in DNTH in Q3 2019 and has held it in 12 quarters since. The position peaked at $15.4K in Q1 2021. 75 funds tracked by Wall St. Rank hold DNTH as of Q2 2022.

Brewin Dolphin Wealth Management held 81 shares of Dianthus Therapeutics worth $2K as of Q2 2022.
Brewin Dolphin Wealth Management left its Dianthus Therapeutics share count unchanged in Q2 2022.
Dianthus Therapeutics made up ﹤0.01% of Brewin Dolphin Wealth Management's portfolio in Q2 2022, its #327 holding.
Brewin Dolphin Wealth Management first reported a position in Dianthus Therapeutics in Q3 2019 and has held it in 12 quarters since.
Brewin Dolphin Wealth Management's Dianthus Therapeutics position peaked at $15.4K in Q1 2021.
75 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q2 2022.

Based on Brewin Dolphin Wealth Management's 13F filing for Q2 2022, filed 14 Nov 2022.